Answers are grounded in this paper and cite their sources.
Background. Sporadic Creutzfeldt–Jakob disease (sCJD) lacks both a disease-modifying therapy and a molecular stratifier, and prior cross-omic analyses of brain transcriptome, blood miRNA, and blood methylation found no shared gene across layers. Methods. We systematically surveyed public human prion-disease expression series, identifying ten eligible records, and reanalysed usable datasets, processing GSE124571 from raw intensities. The four loci whose peripheral blood methylation replicated by pyrosequencing ( FKBP5 , AIM2 , UHRF1 , KCNAB2 ) were evaluated in brain with genome-wide adjustment for microglial cellular composition, alongside a PRNP -depletion dataset and a graded HIV central nervous system (CNS) infection comparator. Results. Two independent brain cohorts replicated across platforms and laboratories (152 shared significant genes,, 99.3% directional agreement). Among the four replicated peripheral methylation loci, AIM2 and UHRF1 were below brain detection thresholds and KCNAB2 was not statistically significant ( and, and ). FKBP5 alone was significantly elevated in frontal cortex (, ) and replicated across regions and sexes where cohort metadata permitted. Although FKBP5 tracked microglial burden, it retained half of its effect after composition adjustment, ranking 14th among 374 equally glia-associated probes while canonical gliosis markers collapsed. While glucocorticoid receptor ( NR3C1 ) transcript sat near background, transcript availability diverged between its co-chaperones: FKBP5 rose while FKBP4 remained flat, shifting their relative log₂ ratio from to. FKBP5 did not respond to PRNP depletion, indicating it is not cell-autonomously -responsive, and reached threefold the elevation observed in HIV encephalitis. Conclusions. sCJD exhibits a transcriptional profile marked by elevated FKBP5 alongside an unmodulated FKBP4 baseline, a pattern consistent with a shift toward low-affinity glucocorticoid-regulating machinery. Because FKBP5 is itself glucocorticoid-induced, exogenous corticosteroids risk deepening this state—consistent with published clinical reports of rapid deterioration following transient or absent benefit. Selective brain-penetrant FKBP51 inhibition (e.g., SAFit2) may offer a non-immunosuppressive alternative to restore costicosteroid signalling dysregulation and suppress NF-κB, warranting head-to-head testing against FK506.
No takes yet. Share an insight, caveat, or question.
Vavougios et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: